Search

Your search keyword '"Korrel M"' showing total 4 results
Start Over Author "Korrel M" Topic adenocarcinoma
4 results on '"Korrel M"'

1. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.

Author

Lof S, Korrel M, van Hilst J, Alseidi A, Balzano G, Boggi U, Butturini G, Casadei R, Dokmak S, Edwin B, Falconi M, Keck T, Malleo G, de Pastena M, Tomazic A, Wilmink H, Zerbi A, Besselink MG, and Abu Hilal M

Subjects
Adenocarcinoma mortality, Adenocarcinoma pathology, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Fluorouracil therapeutic use, Humans, Internationality, Irinotecan therapeutic use, Leucovorin therapeutic use, Male, Middle Aged, Oxaliplatin therapeutic use, Pancreas pathology, Pancreatectomy adverse effects, Pancreatic Fistula epidemiology, Pancreatic Neoplasms mortality, Pancreatic Neoplasms pathology, Postoperative Complications epidemiology, Retrospective Studies, Survival Analysis, Adenocarcinoma therapy, Neoadjuvant Therapy methods, Pancreatic Neoplasms therapy, Propensity Score
Abstract

Background: Several studies have suggested a survival benefit of neoadjuvant therapy (NAT) for pancreatic ductal adenocarcinoma (PDAC) in the pancreatic head. Data concerning NAT for PDAC located in pancreatic body or tail are lacking., Methods: Post hoc analysis of an international multicenter retrospective cohort of distal pancreatectomy for PDAC in 34 centers from 11 countries (2007-2015). Patients who underwent resection after NAT were matched (1:1 ratio), using propensity scores based on baseline characteristics, to patients who underwent upfront resection. Median overall survival was compared using the stratified log-rank test., Results: Among 1236 patients, 136 (11.0%) received NAT, most frequently FOLFIRINOX (25.7%). In total, 94 patients receiving NAT were matched to 94 patients undergoing upfront resection. NAT was associated with less postoperative major morbidity (Clavien-Dindo ≥ 3a, 10.6% vs. 23.4%, P = 0.020) and pancreatic fistula grade B/C (9.6% vs. 21.3%, P = 0.026). NAT did not improve overall survival [27 (95% CI 14-39) versus 31 months (95% CI 19-42), P = 0.277], as compared with upfront resection. In a sensitivity analysis of 251 patients with radiographic tumor involvement of splenic vessels, NAT (n = 37, 14.7%) was associated with prolonged overall survival [36 (95% CI 18-53) versus 20 months (95% CI 15-24), P = 0.049], as compared with upfront resection., Conclusion: In this international multicenter cohort study, NAT for resected PDAC in pancreatic body or tail was associated with less morbidity and pancreatic fistula but similar overall survival in comparison with upfront resection. Prospective studies should confirm a survival benefit of NAT in patients with PDAC and splenic vessel involvement.

Published
2020
Full Text
View/download PDF

2. Laparoscopic extended versus open extended distal pancreatectomy for ductal adenocarcinoma: A pan-European propensity-score matched study.

Author

Balduzzi, A., Van Hilst, J., Korrel, M., Lof, S., Al-Sarireh, B., Alseidi, A., Berrevoet, F., Bjo¨rnsson, B., Van den Boezem, P., Boggi, U., Busch, O., Butturini, G., Casadei, R., Van dam, R., Dokmak, S., Edwin, B., Fabre, J.M., Falconi, M., Forgione, A., and Gayet, B.

Subjects
*PANCREATECTOMY, *LAPAROSCOPIC surgery, *ADENOCARCINOMA
Published
2020
Full Text
View/download PDF

4. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study

Author

Morgan Bonds, M. De Pastena, Giuseppe Malleo, Riccardo Casadei, Safi Dokmak, M. Abu Hilal, Adnan Alseidi, Carlo Lombardo, Tobias Keck, Claudio Ricci, J. van Hilst, Ales Tomazic, Ugo Boggi, Gianpaolo Balzano, Alessandro Giardino, Bjørn Edwin, Guido Fiorentini, Giovanni Capretti, Giovanni Butturini, Massimo Falconi, S. Lof, Maarten Korrel, M.G. Besselink, H. Wilmink, Alessandro Zerbi, Graduate School, Surgery, AGEM - Digestive immunity, AGEM - Endocrinology, metabolism and nutrition, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer Treatment and Quality of Life, Oncology, Lof S., Korrel M., van Hilst J., Alseidi A., Balzano G., Boggi U., Butturini G., Casadei R., Dokmak S., Edwin B., Falconi M., Keck T., Malleo G., de Pastena M., Tomazic A., Wilmink H., Zerbi A., Besselink M.G., Abu Hilal M., Bonds M., Capretti G., Fiorentini G., Giardino A., Lombardo C., and Ricci C.

Subjects
Male, medicine.medical_specialty, Internationality, FOLFIRINOX, medicine.medical_treatment, Leucovorin, Adenocarcinoma, Irinotecan, Gastroenterology, Pancreatic Fistula, Pancreatectomy, Postoperative Complications, Retrospective Studie, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Pancrea, Humans, Prospective cohort study, Propensity Score, Pancreas, Neoadjuvant therapy, Survival analysis, Aged, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocol, business.industry, Pancreatic Neoplasm, Retrospective cohort study, Pancreatic Tumors, Middle Aged, medicine.disease, Survival Analysis, Neoadjuvant Therapy, body regions, Oxaliplatin, Pancreatic Neoplasms, medicine.anatomical_structure, Oncology, Pancreatic fistula, Surgery, Female, Postoperative Complication, Survival Analysi, Fluorouracil, business, Human
Abstract

Background Several studies have suggested a survival benefit of neoadjuvant therapy (NAT) for pancreatic ductal adenocarcinoma (PDAC) in the pancreatic head. Data concerning NAT for PDAC located in pancreatic body or tail are lacking. Methods Post hoc analysis of an international multicenter retrospective cohort of distal pancreatectomy for PDAC in 34 centers from 11 countries (2007–2015). Patients who underwent resection after NAT were matched (1:1 ratio), using propensity scores based on baseline characteristics, to patients who underwent upfront resection. Median overall survival was compared using the stratified log-rank test. Results Among 1236 patients, 136 (11.0%) received NAT, most frequently FOLFIRINOX (25.7%). In total, 94 patients receiving NAT were matched to 94 patients undergoing upfront resection. NAT was associated with less postoperative major morbidity (Clavien–Dindo ≥ 3a, 10.6% vs. 23.4%, P = 0.020) and pancreatic fistula grade B/C (9.6% vs. 21.3%, P = 0.026). NAT did not improve overall survival [27 (95% CI 14–39) versus 31 months (95% CI 19–42), P = 0.277], as compared with upfront resection. In a sensitivity analysis of 251 patients with radiographic tumor involvement of splenic vessels, NAT (n = 37, 14.7%) was associated with prolonged overall survival [36 (95% CI 18–53) versus 20 months (95% CI 15–24), P = 0.049], as compared with upfront resection. Conclusion In this international multicenter cohort study, NAT for resected PDAC in pancreatic body or tail was associated with less morbidity and pancreatic fistula but similar overall survival in comparison with upfront resection. Prospective studies should confirm a survival benefit of NAT in patients with PDAC and splenic vessel involvement.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results